TRENTON, N.J. - Just three months before a top-selling drug gets U.S. generic competition, a generic company has paid nearly $445 million to end a decadelong, twist-filled patent-infringement battle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback